ArticleIranian journal of biotechnology2026
Targeting TPX2 to Enhance Metastasis Control and Radiosensitivity in Esophageal Squamous Cell Carcinoma Through PI3K/AKT Pathway Modulation.
Article in Iranian journal of biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) faces challenges of metastasis and variable radiosensitivity. The role of Targeting Protein for Xenopus Kinesin-like Protein 2 (TPX2) in regulating these ESCC-related traits is unclear, needing investigation. Objectives: This study investigates the functional role of TPX2 in regulating metastasis and radiosensitivity in ESCC. Materials and Methods: Differential expression of TPX2 in ESCC versus normal tissues was verified using bioinformatics (The Cancer Genome Atlas Program, Gene Expression Omnibus) and experimental analyses (Immunohistochemistry, Western blot). ESCC cell lines with stable TPX2 overexpression were established to evaluate effects on migration (wound healing assay), invasion (Transwell assay), and radiotherapy response via colony formation and apoptosis assays. Results: TPX2 was significantly upregulated in ESCC tissues and cell lines. TPX2 overexpression enhanced Conclusion: TPX2 acts as a key regulator of malignant progression and therapeutic response in ESCC by promoting epithelial-mesenchymal transition and activating the PI3K/AKT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.